The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older with HES for 6 months or longer without an identifiable nonhematologic secondary cause. “[This] approval marks the first time in over a decade…
